$MEIP
MEI Pharma, Inc.

2017 Q3 Form 10-Q Financial Statement

#000119312517336509 Filed on November 08, 2017

View on sec.gov

Income Statement

Concept 2017 Q3 2016 Q3
Revenue $283.0K $1.096M
YoY Change -74.18%
Cost Of Revenue $618.0K $1.094M
YoY Change -43.51%
Gross Profit -$335.0K $2.000K
YoY Change -16850.0%
Gross Profit Margin -118.37% 0.18%
Selling, General & Admin $2.490M $2.680M
YoY Change -7.09% 46.45%
% of Gross Profit 134000.0%
Research & Development $6.064M $1.646M
YoY Change 268.41% -41.55%
% of Gross Profit 82300.0%
Depreciation & Amortization $14.00K $14.00K
YoY Change 0.0% -6.67%
% of Gross Profit 700.0%
Operating Expenses $6.064M $1.646M
YoY Change 268.41% -64.57%
Operating Profit -$8.887M -$4.324M
YoY Change 105.53% -6.93%
Interest Expense $100.0K $60.00K
YoY Change 66.67% 100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$8.790M -$4.270M
YoY Change 105.85% -7.58%
Income Tax $1.000K $1.000K
% Of Pretax Income
Net Earnings -$8.788M -$4.270M
YoY Change 105.81% -7.58%
Net Earnings / Revenue -3105.3% -389.6%
Basic Earnings Per Share -$0.24 -$0.12
Diluted Earnings Per Share -$0.24 -$0.12
COMMON SHARES
Basic Shares Outstanding 37.25M shares 35.75M shares
Diluted Shares Outstanding 37.25M shares 35.75M shares

Balance Sheet

Concept 2017 Q3 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $47.00M $58.90M
YoY Change -20.2% 1.55%
Cash & Equivalents $6.958M $13.79M
Short-Term Investments $40.10M $45.10M
Other Short-Term Assets $600.0K $1.700M
YoY Change -64.71% 183.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $47.66M $60.64M
YoY Change -21.4% 3.46%
LONG-TERM ASSETS
Property, Plant & Equipment $45.00K $46.00K
YoY Change -2.17% -25.81%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $367.0K $403.0K
YoY Change -8.93% -11.23%
TOTAL ASSETS
Total Short-Term Assets $47.66M $60.64M
Total Long-Term Assets $367.0K $403.0K
Total Assets $48.03M $61.05M
YoY Change -21.32% 3.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $751.0K $749.0K
YoY Change 0.27% 196.05%
Accrued Expenses $2.767M $2.428M
YoY Change 13.96% -15.52%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.465M $17.22M
YoY Change -74.07% 450.69%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.500M
YoY Change
Total Long-Term Liabilities $0.00 $1.500M
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.465M $17.22M
Total Long-Term Liabilities $0.00 $1.500M
Total Liabilities $4.500M $18.71M
YoY Change -75.95% 503.68%
SHAREHOLDERS EQUITY
Retained Earnings -$183.1M -$181.3M
YoY Change 1.02% 12.76%
Common Stock $226.7M $223.6M
YoY Change 1.38% 3.19%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $43.57M $42.33M
YoY Change
Total Liabilities & Shareholders Equity $48.03M $61.05M
YoY Change -21.32% 3.35%

Cashflow Statement

Concept 2017 Q3 2016 Q3
OPERATING ACTIVITIES
Net Income -$8.788M -$4.270M
YoY Change 105.81% -7.58%
Depreciation, Depletion And Amortization $14.00K $14.00K
YoY Change 0.0% -6.67%
Cash From Operating Activities -$6.562M $8.770M
YoY Change -174.82% -252.26%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $2.000K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $5.040M -$10.03M
YoY Change -150.25% -303.86%
Cash From Investing Activities $5.042M -$10.03M
YoY Change -150.27% -303.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $4.212M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 20.00K 4.210M
YoY Change -99.52%
NET CHANGE
Cash From Operating Activities -6.562M 8.770M
Cash From Investing Activities 5.042M -10.03M
Cash From Financing Activities 20.00K 4.210M
Net Change In Cash -1.500M 2.950M
YoY Change -150.85% -451.19%
FREE CASH FLOW
Cash From Operating Activities -$6.562M $8.770M
Capital Expenditures $0.00 $2.000K
Free Cash Flow -$6.562M $8.768M
YoY Change -174.84%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37014947 shares
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13789000
CY2017Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
113000000 shares
CY2017Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36950000 shares
CY2017Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00000002
CY2017Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36950000 shares
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2653495 shares
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.96
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5696755 shares
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.12
CY2017Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2017Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-183119000
CY2017Q3 us-gaap Assets
Assets
48031000
CY2017Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
322000
CY2017Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
641000
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3458176
CY2017Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
48031000
CY2017Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
947000
CY2017Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
751000
CY2017Q3 us-gaap Stockholders Equity
StockholdersEquity
43566000
CY2017Q3 us-gaap Common Stock Value
CommonStockValue
0
CY2017Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
226685000
CY2017Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2017Q3 us-gaap Contractual Obligation
ContractualObligation
1400000
CY2017Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4465000
CY2017Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2767000
CY2017Q3 us-gaap Assets Current
AssetsCurrent
47664000
CY2017Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
45000
CY2017Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1787193
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6958000
CY2017Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
47023000
CY2017Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
3600000
CY2017Q3 us-gaap Short Term Investments
ShortTermInvestments
40065000
CY2017Q3 meip Shelf Registration Statement Value
ShelfRegistrationStatementValue
150000000
CY2017Q3 meip Accrued Milestone Payments
AccruedMilestonePayments
0
CY2017Q3 meip Milestone Payments Maximum Amount
MilestonePaymentsMaximumAmount
75200000
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10837000
CY2017Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
113000000 shares
CY2017Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36772000 shares
CY2017Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00000002
CY2017Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36772000 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4259083 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.21
CY2017Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2017Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-174331000
CY2017Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55704000
CY2017Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
996000
CY2017Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
585000
CY2017Q2 us-gaap Stockholders Equity
StockholdersEquity
50838000
CY2017Q2 us-gaap Common Stock Value
CommonStockValue
0
CY2017Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
225169000
CY2017Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2017Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4866000
CY2017Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3285000
CY2017Q2 us-gaap Assets Current
AssetsCurrent
55323000
CY2017Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
50000
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8458000
CY2017Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
53565000
CY2017Q2 us-gaap Short Term Investments
ShortTermInvestments
45107000
CY2017Q2 us-gaap Assets
Assets
55704000
CY2017Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
331000
CY2017Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1758000
CY2012Q3 us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
500000
CY2016Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8122000 shares
CY2016Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2016Q3 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
8773000
CY2016Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M25D
CY2016Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35747000 shares
CY2016Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35747000 shares
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.012 pure
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.12
CY2016Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
35436000 shares
CY2016Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2016Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0 shares
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.082 pure
CY2016Q3 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
311000 shares
CY2016Q3 us-gaap Revenues
Revenues
1096000
CY2016Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2000
CY2016Q3 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
1096000
CY2016Q3 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
20054000
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4324000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-4270000
CY2016Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
55000
CY2016Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
910000
CY2016Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
14000
CY2016Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2016Q3 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-330000
CY2016Q3 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-10033000
CY2016Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4212000
CY2016Q3 us-gaap Share Based Compensation
ShareBasedCompensation
737000
CY2016Q3 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
15537000
CY2016Q3 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
10023000
CY2016Q3 us-gaap Costs And Expenses
CostsAndExpenses
5420000
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2680000
CY2016Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2005000
CY2016Q3 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
4212000
CY2017Q3 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2017Q3 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2017Q3 dei Document Type
DocumentType
10-Q
CY2017Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2017Q3 dei Entity Central Index Key
EntityCentralIndexKey
0001262104
CY2017Q3 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-6562000
CY2017Q3 dei Amendment Flag
AmendmentFlag
false
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
72343 shares
CY2017Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3M19D
CY2017Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.73
CY2017Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
3.01
CY2017Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M25D
CY2017Q3 dei Trading Symbol
TradingSymbol
MEIP
CY2017Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37245000 shares
CY2017Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37245000 shares
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1646000
CY2016Q3 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2952000
CY2016Q3 us-gaap Cost Of Services
CostOfServices
1094000
CY2017Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9179000 shares
CY2017Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.45
CY2017Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.84
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.021 pure
CY2017Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y4M24D
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
70778 shares
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.21
CY2017Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
36845000 shares
CY2017Q3 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2017Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2017Q3 dei Document Period End Date
DocumentPeriodEndDate
2017-09-30
CY2017Q3 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1592000 shares
CY2017Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
11207 shares
CY2017Q3 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. We use estimates that affect the reported amounts (including assets, liabilities, revenues and expenses) and related disclosures. Actual results could materially differ from those estimates.</p> </div>
CY2017Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0 shares
CY2017Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M18D
CY2017Q3 dei Entity Registrant Name
EntityRegistrantName
MEI Pharma, Inc.
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.976 pure
CY2017Q3 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
400000 shares
CY2017Q3 us-gaap Revenues
Revenues
283000
CY2017Q3 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
283000
CY2017Q3 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
4999000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8887000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-8788000
CY2017Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
100000
CY2017Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1117000
CY2017Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
14000
CY2017Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2017Q3 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
166000
CY2017Q3 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
5042000
CY2017Q3 us-gaap Share Based Compensation
ShareBasedCompensation
996000
CY2017Q3 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-49000
CY2017Q3 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
10041000
CY2017Q3 us-gaap Costs And Expenses
CostsAndExpenses
9170000
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2488000
CY2017Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-18000
CY2017Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
44000
CY2017Q3 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
20000
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6064000
CY2017Q3 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1500000
CY2017Q3 us-gaap Cost Of Services
CostOfServices
618000
CY2017Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
20000
CY2017Q3 meip Lease Arrangement Rent Area
LeaseArrangementRentArea
13700 sqft
CY2017Q3 meip Lease Commencement Month And Year
LeaseCommencementMonthAndYear
2017-06
CY2017Q3 meip Percentage Of Purchases From Major Suppliers
PercentageOfPurchasesFromMajorSuppliers
1.00 pure
CY2017Q3 meip Agreement Termination Notice Period
AgreementTerminationNoticePeriod
P90D
CY2017Q3 meip Lease Expiration Month And Year
LeaseExpirationMonthAndYear
2020-05

Files In Submission

Name View Source Status
0001193125-17-336509-index-headers.html Edgar Link pending
0001193125-17-336509-index.html Edgar Link pending
0001193125-17-336509.txt Edgar Link pending
0001193125-17-336509-xbrl.zip Edgar Link pending
d445348d10q.htm Edgar Link pending
d445348dex101.htm Edgar Link pending
d445348dex311.htm Edgar Link pending
d445348dex312.htm Edgar Link pending
d445348dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
meip-20170930.xml Edgar Link completed
meip-20170930.xsd Edgar Link pending
meip-20170930_cal.xml Edgar Link unprocessable
meip-20170930_def.xml Edgar Link unprocessable
meip-20170930_lab.xml Edgar Link unprocessable
meip-20170930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending